Last reviewed · How we verify
Human epidermal growth factor 2 positive gastric cancer
Approved treatments
- OGIVRI · MYLAN GMBH
- Herceptin · Roche
Trastuzumab inhibits proliferation of HER2-overexpressing tumor cells and mediates antibody-dependent cellular cytotoxicity. - Herceptin · Roche
HER2-targeted antibody-drug conjugate delivering microtubule inhibitor DM1 to HER2-overexpressing cells. - Herceptin · National Cancer Institute (NCI)
- Trastuzumab (Herceptin) · Pfizer Inc.
Clinical guidelines
- FDA label — 1L
TRAZIMERA is indicated in combination with cisplatin and capecitabine or 5-fluorouracil for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Human epidermal growth factor 2 positive gastric cancer patent landscape — cliff calendar, originator estates, attackable patents
- Human epidermal growth factor 2 positive gastric cancer treatment landscape brief
- Human epidermal growth factor 2 positive gastric cancer treatment updates RSS
Frequently asked questions about Human epidermal growth factor 2 positive gastric cancer
What drugs treat Human epidermal growth factor 2 positive gastric cancer?
Tracked treatments include OGIVRI, Herceptin, Trastuzumab (Herceptin).
What is the treatment for Human epidermal growth factor 2 positive gastric cancer?
Standard treatment for Human epidermal growth factor 2 positive gastric cancer includes OGIVRI, Herceptin, Trastuzumab (Herceptin). See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Human epidermal growth factor 2 positive gastric cancer?
FDA label publishes guidelines for Human epidermal growth factor 2 positive gastric cancer. 1 guideline references tracked.
Related
- Treatment landscape: Human epidermal growth factor 2 positive gastric cancer patent cliff · Human epidermal growth factor 2 positive gastric cancer CI report
- Treatment: OGIVRI · MYLAN GMBH
- Treatment: Herceptin · Roche
- Treatment: Herceptin · Roche
- Treatment: Herceptin · National Cancer Institute (NCI)
- Treatment: Trastuzumab (Herceptin) · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing